Search
Kiniksa Pharmaceuticals International PLC
KNSAAdd to Watchlist
58.248USD
+1.118+1.96%
Market hours （ET）Quotes delayed by 15 min
4.44BMarket Cap
59.87P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.96%
5 Days
+11.29%
1 Month
+9.41%
6 Months
+33.84%
Year to Date
+41.21%
1 Year
+104.81%
Key Figures
57.000Open
58.875High
226.71KVolume
59.87P/E TTM
28.76P/E Dynamic
--Dividend TTM
0.30%Turnover Ratio
57.130Prev. Close
56.500Low
10.76MTurnover
LossP/E Static
7.83P/B
0.00%Div Yield TTM
10.26%ROA
59.87052wk High
1.11Volume Ratio
-43.19MNet Profit
76.29MShares
0.9729EPS TTM
0.14Beta
13.74%ROE
26.27052wk Low
4.16%Amplitude
90.29%Gross Margin
4.44BMarket Cap
2.91Reward/Risk
2.23%Risk Rate
TradingKey Stock Score of Kiniksa Pharmaceuticals International PLC
Currency: USD Updated: 2026-06-22Key Insights
Kiniksa Pharmaceuticals International PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 4 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 62.29.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kiniksa Pharmaceuticals International PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Kiniksa Pharmaceuticals International PLC Highlights
StrengthsRisks
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 150.71% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 677.56M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 58.72, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 51.67M shares, increasing 4.10% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 19.48K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
62.286
Target Price
+13.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Kiniksa Pharmaceuticals International PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kiniksa Pharmaceuticals International PLC Info
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Ticker SymbolKNSA
CompanyKiniksa Pharmaceuticals International PLC
CEOPatel (Sanjiv K)
Websitehttps://www.kiniksa.com/
Related Instruments
-0.40%
+1.64%
+1.76%
+1.61%
+2.25%
+2.04%
+0.59%
+1.35%
+0.62%
-0.78%
-0.14%
+1.01%
+1.82%
-0.08%
+2.90%
0.00%
+0.40%
+2.34%
+1.31%
+1.87%Popular Instruments
72.945
-1.044 (-1.41%)
297.695
+0.685 (+0.23%)
201.025
-7.625 (-3.65%)
4136.380
-53.870 (-1.29%)
664.571
-68.049 (-9.29%)
1987.520
-286.210 (-12.59%)
1079.200
-132.180 (-10.91%)
345.340
-4.340 (-1.24%)
62298.880
-2104.920 (-3.27%)
382.660
-22.390 (-5.53%)
FAQs
What is the current price of Kiniksa Pharmaceuticals International PLC (KNSA)?
The current price of Kiniksa Pharmaceuticals International PLC (KNSA) is 57.09.
What is the symbol of Kiniksa Pharmaceuticals International PLC?
The ticker symbol of Kiniksa Pharmaceuticals International PLC is KNSA.
What is the 52-week high of Kiniksa Pharmaceuticals International PLC?
The 52-week high of Kiniksa Pharmaceuticals International PLC is 59.87.
What is the 52-week low of Kiniksa Pharmaceuticals International PLC?
The 52-week low of Kiniksa Pharmaceuticals International PLC is 26.27.
What is the market capitalization of Kiniksa Pharmaceuticals International PLC?
The market capitalization of Kiniksa Pharmaceuticals International PLC is 4.40B.
Is Kiniksa Pharmaceuticals International PLC (KNSA) currently rated as Buy, Hold, or Sell?
According to analysts, Kiniksa Pharmaceuticals International PLC (KNSA) has an overall rating of Buy, with a price target of 62.29.
What is the Earnings Per Share (EPS TTM) of Kiniksa Pharmaceuticals International PLC (KNSA)?
The Earnings Per Share (EPS TTM) of Kiniksa Pharmaceuticals International PLC (KNSA) is 0.80.
